Olema Pharmaceuticals, Inc. (OLMA)
$10.43-2.43%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-07-31
- Market cap
- $911M
- Avg volume
- 1.3M
- Beta
- 2.01
- P/E (TTM)
- -4.92
- Short % float
- 22.54%
- Days to cover
- 18.2
- SI change
- +5.7%
- 1W
- -3.16%
- 1M
- -10.85%
- 3M
- -23.76%
- YTD
- -58.74%
- vs SPY 1W
- -1.97%
- vs SPY 1M
- -14.18%
- vs SPY 3M
- -26.15%
- vs SPY YTD
- -70.50%
Sector peers
Same-sector names ranked by LOPJLB quality proximity · Healthcare
- AURABUYAura Biosciences, Inc.RECOVERYQ -3$7.90+1.28%
- AVBPSELLArriVent BioPharma, Inc. Common StockRECOVERYQ 21$28.26-2.95%
- AVLNBUYAvalyn Pharma Inc. Common StockQ 75$37.69-1.77%
- CLYMBUYClimb Bio, Inc.BULLQ 11$16.40-5.09%
- COAGBUYHemab Therapeutics Holdings, Inc. Common StockQ 70$46.67-5.07%
- DFTXSELLDefinium Therapeutics, Inc.RECOVERYQ 27$43.27-3.65%
- ELDNSELLEledon Pharmaceuticals, Inc.RECOVERYQ -11$3.41-1.16%
- ELVNBUYEnliven Therapeutics, Inc.BULLQ 15$61.15+2.22%
- EPRXBUYEupraxia Pharmaceuticals Inc.RECOVERYQ 46$7.28+8.17%
- GHRSBUYGH Research PLCBEARQ 19$28.10-0.81%
- GPCRBUYStructure Therapeutics Inc.RECOVERYQ 27$49.01-0.16%
- IMMXBUYImmix Biopharma, Inc.RECOVERYQ 29$13.61-0.37%
Industry peers
FMP comparable companies · ranked by market cap
- ABSIBUYAbsci Corporation$1.6BCRISISQ 1$9.55-7.43%
- KALVBUYKalVista Pharmaceuticals, Inc.$1.4BBULLQ 9$27.00+0.00%
- CRVSBUYCorvus Pharmaceuticals, Inc.$1.2BRECOVERYQ 14$14.46-2.56%
- LXRXSELLLexicon Pharmaceuticals, Inc.$1.0BBEARQ 6$2.30+0.87%
- VTYXVentyx Biosciences, Inc.$1.0B$14.00
- FDMTBUY4D Molecular Therapeutics, Inc.$828MRECOVERYQ 5$15.83-2.78%
- VSTMBUYVerastem, Inc.$605MRECOVERYQ 3$6.89-0.44%
- RGNXSELLREGENXBIO Inc.$554MCRISISQ -2$10.72-24.81%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 20
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-28.9%
REV YoY-
ROE-48.2%
EPS YoY-
ROA-42.0%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-4.92
P/E FWD-
SECTOR PE22.66
INDUSTRY PE17.07
P/B2.53
P/FCF-
EV/EBITDA-4.23
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.15
ALTMAN Z-
CURR RATIO8.86
ND/EBITDA-
BETA2.01
